Chengda Pharmaceutical (301201.SZ) announced its first-half results, with net profit of 2.2997 million yuan to mother, a year-on-year decrease of 82.07%

According to the Zhitong Finance App, Chengda Pharmaceutical (301201.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 255 million yuan, an increase of 40.03% over the previous year. Net profit attributable to shareholders of listed companies was 2.2997 million yuan, a year-on-year decrease of 82.07%. Net loss of 5.272,600 yuan for non-recurring profit and loss attributable to shareholders of listed companies is deducted.

During the reporting period, the company's revenue increased and profits declined. The main factors were: (1) The new workshop production capacity of the fund-raising projects in the first half of 2026 was released one after another. The depreciation and amortization of products increased more than in the same period of the previous year, and the cost increased significantly, leading to a decline in overall gross margin; (2) As export revenue grew, the company experienced a net exchange loss; (3) In the reporting period, R&D expenses increased significantly; (4) During the reporting period, the company complies with Long-term equity investments calculated under the equity method have a reduced value of 4.437,600 yuan.